11 recruiting. 11 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 11 |
| Phase 2 | 7 | Recruiting 7 |
Follow CRC: new trials by email Literature Review of CRC trials Research Report on CRC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 152 | 2026-11-01 | 2026-11-02 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-08-03 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer CBI-1214 - Colorectal Cancer, Colorectal Cancer (CRC) | Phase 1 | Recruiting | Cartography Biosciences | 80 | 2026-01-15 | 2026-08-26 |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors RMC-5127, daraxonrasib, cetuximab - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Recruiting | Revolution Medicines, Inc. | 574 | 2026-01-08 | 2026-09-17 |
| A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin, Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin, Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine - CRC | Phase 1 / Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 502 | 2025-12-22 | 2026-05-01 |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer HCB101, Bevacizumab, Cetuximab (Erbitux) - CRC | Phase 1 / Phase 2 | Recruiting | Chang Gung Memorial Hospital | 40 | 2025-05-14 | 2025-10-02 |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors TUB-030 - Advanced Solid Tumors, HNSCC | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 250 | 2024-12-13 | 2026-09-11 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors RMC-6236, mFOLFOX6 regimen, bevacizumab - Colorectal Cancer, CRC | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 1130 | 2024-05-24 | 2026-09-22 |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression A2B694, A2B543, xT CDx with HLA-LOH Assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 474 | 2024-04-03 | 2026-06-12 |
| A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody - Solid Tumor, HNSCC | Phase 1 | Recruiting | SparX Biotech(Jiangsu) Co., Ltd. | 232 | 2024-03-20 | 2024-09-24 |
Colorectal Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (5) · Squamous Cell Carcinoma of Head and Neck (4) · Colonic Neoplasms (3) · Lung Neoplasms (3) · Neoplasms (3) · Pancreatic Neoplasms (3) · Rectal Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Pancreatic Ductal (1) · Carcinoma, Renal Cell (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Mesothelioma (1)
Neoplasms by Site (9) · Colonic Diseases (7) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Gastrointestinal Diseases (7) · Intestinal Diseases (7) · Intestinal Neoplasms (7) · Rectal Diseases (7) · Gastrointestinal Neoplasms (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Bronchial Neoplasms (5) · Carcinoma (5) · Carcinoma, Bronchogenic (5)
Cetuximab (4) · Bevacizumab (2) · 130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · Cisplatin (1) · Fluorouracil (1) · Folfox protocol (1) · Gemcitabine (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · Pemetrexed (1) · Therapeutics (1) · X-Rays (1)
Revolution Medicines, Inc. (3) · A2 Biotherapeutics Inc. (2) · Aktis Oncology, Inc. (1) · Cartography Biosciences (1) · Chang Gung Memorial Hospital (1) · Gilead Sciences (1) · Hansoh BioMedical R&D Company (1) · SparX Biotech(Jiangsu) Co., Ltd. (1)
United States (9) · Canada (1) · China (1) · France (1) · Romania (1) · Spain (1) · Taiwan (1)
John Welch, MD, PhD (2) · Guidong Zhu (1) · Hung-Chih Hsu (1) · Yariv Houvras, MD, PhD (1)